Jonathan Chang
Stock Analyst at Leerink Partners
(0.33)
# 3,538
Out of 4,667 analysts
91
Total ratings
25%
Success rate
-23.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VINC Vincerx Pharma | Maintains: Outperform | $4 → $2 | $0.28 | +625.69% | 6 | Oct 8, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $32.42 | +128.25% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $4.07 | +170.37% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $16.86 | +202.49% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $6 → $5 | $0.78 | +545.16% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $11.23 | +202.76% | 9 | Dec 7, 2022 | |
| GMAB Genmab | Maintains: Market Perform | $31 → $33 | $20.45 | +61.37% | 9 | Nov 10, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $20.36 | +145.58% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $57.07 | -47.43% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $3.28 | +265.85% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $2.22 | +530.63% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $7.80 | +233.33% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $26.23 | +262.18% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.66 | +351.33% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $15.91 | +75.99% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $23.72 | +123.44% | 7 | Aug 5, 2021 |
Vincerx Pharma
Oct 8, 2024
Maintains: Outperform
Price Target: $4 → $2
Current: $0.28
Upside: +625.69%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $32.42
Upside: +128.25%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $4.07
Upside: +170.37%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $16.86
Upside: +202.49%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $6 → $5
Current: $0.78
Upside: +545.16%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $11.23
Upside: +202.76%
Genmab
Nov 10, 2022
Maintains: Market Perform
Price Target: $31 → $33
Current: $20.45
Upside: +61.37%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $20.36
Upside: +145.58%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $57.07
Upside: -47.43%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $3.28
Upside: +265.85%
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $2.22
Upside: +530.63%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $7.80
Upside: +233.33%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $26.23
Upside: +262.18%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.66
Upside: +351.33%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $15.91
Upside: +75.99%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $23.72
Upside: +123.44%